BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2300478
,
BRAF
,
glucose metabolic process
,
Diabetes mellitus
,
Adipose tissue
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
braf protein, mouse
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Prostate cancer mouse models treated with different compounds
Murine melanoma SB-3123 cell line treated with IFNgamma, TNFalpha & BRAFV600E inhibitor vemurafenib
TWEAK-treated time course in Pan02 pancreatic cancer cells
Osteosarcoma cell line U2OS response to treatment with TWEAK
TWEAK-treated time course in MDA-MB-436 breast cancer cells
Explore Curated Studies Results
Literature
Most Relevant Literature
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse mode…
Immunologic effects of an orally available BRAFV600E inhibitor in BRAF wild-type murine models.
Targeting BRAFV600E in an inducible murine model of melanoma.
Cryptotanshinone has diverse effects on cell cycle events in melanoma cell lines with different meta…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastat…
Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance …
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanom…
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ